- Business Wire•3 days agoIpsen appoints Harout Semerjian as President, Head of Specialty Care International Region & Global Franchises
- Business Wire•5 days agoCORRECTING and REPLACING Ipsen Biopharmaceuticals, Inc. Announces Poster Presentations at ASCO 2017 Gastrointestinal Cancers Symposium
First bulletpoint should read as "Study of lanreotide depot..."
- Reuters•14 days ago
The deal would give Merrimack the resources to fund the development of three new compounds targeting pancreatic, lung, and other types of cancers. It would boost Ipsen's portfolio, which has traditionally focused on endocrinology. Ipsen will pay $575 million at the closing of the deal and up to $450 million more, contingent on some approvals for Onivyde in the United States.
IPN.PA : Summary for IPSEN - Yahoo Finance
Ipsen S.A. (IPN.PA)
Paris - Paris Delayed Price. Currency in EUR
Add to watchlist
|Bid||53.26 x 46200|
|Ask||53.99 x 2000|
|Day's Range||71.01 - 71.80|
|52 Week Range||45.31 - 74.77|
|PE Ratio (TTM)||25.26|
|Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|